Prof David M Reid
Division of Applied Medicine
University of Aberdeen
+44 1224 51154
That co-treatment of patients receiving potent nitrogen containing bisphosphonates (N-BP), with a statin, would prevent the activation and increase in gamma,delta-T cells and therefore prevent the subsequent acute phase response that occurs after the infusion of the N-BP.
Grampian Local Research Ethics Committee. Date of approval: 24/03/2005 (ref: 05/S0801/39)
Single-centre, randomised controlled trial.
Primary study design
Secondary study design
Randomised controlled trial
Patient information sheet
Not available in web format, please use the contact details below to request a patient information sheet
The participants will be randomly allocated to the following three arms:
Arm 1: Oral fluvastatin (40 mg immediate release formulation) immediately prior to an intravenous (iv) infusion of zoledronic acid (5 mg) + an oral dose placebo fluvastatin on the 1st and 2nd day after the infusion.
Arm 2: Single dose of matching placebo fluvastatin, immediately prior to an infusion of zoledronic acid (5 mg) and an oral dose placebo fluvastatin on the 1st and 2nd day after the infusion.
Arm 3: Oral dose of fluvastatin (40 mg immediate release formulation) immediately prior to an iv infusion of zoledronic acid (5 mg) + an oral dose of fluvastatin on the 1st and 2nd day after the bisphosphonate infusion.
Bisphosphonates, zoledronic acid and fluvastatin.
Primary outcome measure
Serum C reactive protein (CRP) at 72 hours.
Secondary outcome measures
1. Changes in cytokines (tumour necrosis factor-alpha [TNF-alpha], interleukin-6 [IL-6] and interferon gamma) at 24 hours
2. Changes in serum cholesterol at 48 hours
3. Alterations in temperature post infusion (at 24 hours)
4. Alterations in acute phase response as assessed by questionnaire at 72 hours
Overall trial start date
Overall trial end date
Reason abandoned (if study stopped)
Participant inclusion criteria
1. Postmenopausal women over the age of 20 and more than 12 months after cessation of menses or with serum estradiol and/or follicle stimulating hormone (FSH) levels consistent with a post-menopausal state, but <= 10 years post menopause
2. Bisphosphonate naïve women with osteopenia as defined by the World Health Organization (WHO) (T-score <= 1.0 but >-2.5) or osteoporosis as defined by the WHO (T-score <-2.5) at the lumbar spine or total hip Bone Mineral Density (BMD) measurement sites
3. Women willing and able to give informed consent
Target number of participants
Participant exclusion criteria
1. The patient has a history of hypersensitivity to any statin or previously exposed to fluvastatin
2. The patient has a history of any illness or has significant abnormalities on pre-study clinical or laboratory evaluation which, in the opinion of the investigator, might either pose an unacceptable risk to the patient from participation in this study or complicate the interpretation of study data
3. The patient is a current user of any illicit drugs or has a history of drug or alcohol abuse within the past five years
4. The patient has a history of or evidence for metabolic bone disease (other than postmenopausal bone loss) including but not limited to vitamin D deficiency, hypoparathyroidism, primary hyperparathyroidism, recent hyperthyroidism (suppressed thyroid stimulating hormone [TSH] within the six months prior to entry into the study), Paget's disease of bone, osteomalacia or renal osteodystrophy
5. The patient has any other disease potentially associated with increased bone turnover including, but not exclusive to, rheumatoid arthritis, Crohn's disease, severe renal impairment or severe hepatic disease
6. The patient has a history of cancer except for the following:
6.1. Superficial basal or squamous cell carcinoma of the skin which has been completely resected
6.2. Stage I breast cancer (lesion <= 3 cm with no nodal or local invasion) which has been completely treated more than one year ago with no evidence of recurrence
6.3. Other malignancies completely treated without recurrence or treatment in the last 5 years
7. Baseline renal insufficiency defined as either baseline creatinine of >177 mmol/l and/or calculated creatinine clearance of < 40ml/min
8. Serum 25-OH vitamin D level <15 ng/ml
9. Serum calcium <2 mmol/L and >2.75 mmol/L
10. Serum alkaline phosphatase >1.5x Upper Limit of Normal (ULN) and/or aspartate aminotransferase (AST) or alanine aminotransferase (ALT) >2 x ULN
11. The patient is receiving or has received treatment prior to randomisation which might influence bone turnover, including:
11.1. Any treatment with parathyroid hormone during the year prior to randomisation
11.2. Within the last 6 months: oestrogen, oestrogen analogues (e.g., raloxifene, tamoxifen), tibolone or anabolic steroids. Oestrogen taken >3 months ago for <= 1 week is acceptable. Topical (vaginal) oestrogen cream (<= 2 g) used up to two times weekly is acceptable
11.3. Thyroid hormone, unless on a stable dose for at least six weeks before randomisation with serum TSH within the normal range; patients found at screening to have mild hypothyroidism (as indicated by an elevation in TSH to no more than 15 µIU/ml) are eligible to enter the study provided they receive careful thyroid replacement therapy, if needed, and TSH levels are monitored three months later and as appropriate during the study
11.4. Glucocorticoid treatment for more than one month with >7.5 mg of oral prednisone (or the equivalent) per day within six months prior to randomisation; high-dose, intravenously within 6 months prior to randomisation; patients who have received therapeutic glucocorticoids in the past must be considered highly unlikely to require retreatment (with >7.5 mg of oral prednisone daily or the equivalent for more than one month or <= 500 mg of methylprednisolone pulse at any time) during the course of the study
12. Treatment with an immunosuppressant (e.g., cyclosporine, azathioprine) within the previous year
13. The patient is receiving or is expected to receive during the course of the study any medication (other than study medication) that might alter bone or calcium metabolism, including vitamin D in excess of 5000 IU per day, calcitonin, phenytoin, heparin, or lithium
14. HIV patients
15. No History of uveitis, iritis or conjunctivitis
16. No history of retinopathy or nephropathy especially in the presence of uncontrollable insulin dependent diabetes mellitus HB1AC >10%.
17. Any patient with severe dental problems or current dental infections, or with recent or pending surgery within 3 months of dosing
Recruitment start date
Recruitment end date
Countries of recruitment
Trial participating centre
Division of Applied Medicine
Novartis Pharmaceuticals (Switzerland)
Funding Body Type
Funding Body Subtype
Results and Publications
Publication and dissemination plan
Not provided at time of registration
Intention to publish date
Participant level data
Not provided at time of registration
Basic results (scientific)
1. 2010results in http://www.ncbi.nlm.nih.gov/pubmed/21047568
Thompson K, Keech F, McLernon DJ, Vinod K, May RJ, Simpson WG, Rogers MJ, Reid DM, Fluvastatin does not prevent the acute-phase response to intravenous zoledronic acid in post-menopausal women., Bone, 2011, 49, 1, 140-145, doi: 10.1016/j.bone.2010.10.177.